A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease

被引:24
作者
Davies, E. H.
Surtees, R.
DeVile, C.
Schoon, I.
Vellodi, A.
机构
[1] Inst Child Hlth, London WC1N 1EH, England
[2] UCL, Inst Child Hlth, Great Ormond St Hosp Children NHS Trust, Clin & Mol Genet Unit,Biochem Res Grp, London, England
[3] Great Ormond St Hosp Sick Children, Dept Neurosci, London WC1N 3JH, England
[4] City Univ London, London EC1V 0HB, England
关键词
D O I
10.1007/s10545-007-0595-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type III Gaucher disease is one of the three recognized subtypes of Gaucher disease, an inherited deficiency of lysosomal glucocerebrosidase. Phenotypically there is a wide spectrum of visceral and neurological manifestations. Enzyme replacement is effective in managing the visceral disease; however, the neurological manifestations remain a more challenging obstacle. There is an unfulfilled need to reliably monitor neurological disease and its response to treatment. A severity scoring tool was developed through neurological domain identification, item generation and tool formation. Domain identification was established based on a retrospective single centre study (n=15) and a systematic review of publications. Forty-seven patients with neuronopathic Gaucher disease were then assessed using the tool to establish the clinical and statistical reliability of each domain. Judgement quantification of the tool was established through a process of content validity involving five European experts. Content validity is considered to be most effective when undertaken systematically. Concurrent validity and feasibility of the tool was also highlighted. This process allowed a revised and validated version of the tool to be developed.
引用
收藏
页码:768 / 782
页数:15
相关论文
共 28 条
[1]   GAUCHERS-DISEASE VARIANT CHARACTERIZED BY PROGRESSIVE CALCIFICATION OF HEART-VALVES AND UNIQUE GENOTYPE [J].
ABRAHAMOV, A ;
ELSTEIN, D ;
GROSSTSUR, V ;
FARBER, B ;
GLASER, Y ;
HADASHALPERN, I ;
RONEN, S ;
TAFAKJDI, M ;
HOROWITZ, M ;
ZIMRAN, A .
LANCET, 1995, 346 (8981) :1000-1003
[2]   The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease [J].
Altarescu, G ;
Hill, S ;
Wiggs, E ;
Jeffries, N ;
Kreps, C ;
Parker , CC ;
Brady, RO ;
Barton, NW ;
Schiffmann, R ;
Bannarjee, TK ;
Crutchfield, K ;
Frei, K ;
McKee, MA ;
Moore, DF ;
Tournay, A .
JOURNAL OF PEDIATRICS, 2001, 138 (04) :539-547
[3]  
[Anonymous], 2005, Clinical Effectiveness in Nursing, DOI DOI 10.1016/J.JOON.2006.08.001
[4]  
Bowling A, 2001, Measuring Disease.
[5]  
DeVellis RF., 2017, SCALE DEV THEORY APP
[6]   GAUCHER DISEASE - NORRBOTTNIAN TYPE .1. GENERAL CLINICAL DESCRIPTION [J].
DREBORG, S ;
ERIKSON, A ;
HAGBERG, B .
EUROPEAN JOURNAL OF PEDIATRICS, 1980, 133 (02) :107-118
[7]  
DURLING E, 2006, EUROPEAN WORKING GRO
[8]   Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease [J].
Erikson, A ;
Forsberg, H ;
Nilsson, M ;
Åström, M ;
Månsson, JE .
ACTA PAEDIATRICA, 2006, 95 (03) :312-317
[9]   ENZYME INFUSION THERAPY OF THE NORRBOTTNIAN (TYPE-3) GAUCHER DISEASE [J].
ERIKSON, A ;
ASTROM, M ;
MANSSON, JE .
NEUROPEDIATRICS, 1995, 26 (04) :203-207
[10]  
GIBSON F, 2006, EUR J CANCER, V42, P1